2021
THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS
Li M, Khan S, Proctor D, Gaidos J, Al-Bawardy B. THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS. Inflammatory Bowel Diseases 2021, 27: s45-s46. DOI: 10.1093/ibd/izaa347.110.Peer-Reviewed Original ResearchInflammatory bowel diseaseBiologic agentsAdverse eventsSmall molecule therapiesClinical remissionMucosal healingBowel diseaseConcomitant cirrhosisConcomitant corticosteroid therapyDifferent biologic agentsPrimary sclerosing cholangitisQuarter of patientsCohort of patientsEffectiveness of biologicsSmall molecule agentsConcomitant thiopurinesCorticosteroid therapyIBD patientsIBD therapyCertolizumab pegolSclerosing cholangitisAdult patientsBiologic therapyInfusion reactionsSecondary outcomes
2017
Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease
Feagins LA, Waljee A, Hou JK, Gu P, Kanjo S, Rudrapatna V, Cipher DJ, Govani S, Gaidos J. Incidence of and Predictors for Early Discontinuation of Biological Therapies in Veteran Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2017, 23: 1434-1439. PMID: 28570429, DOI: 10.1097/mib.0000000000001145.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseBiological therapyAdverse drug reactionsConcomitant thiopurinesPrimary nonresponseEarly discontinuationBowel diseaseDrug reactionsDiagnosis of IBDBiological agentsFirst biological agentRetrospective cohort studyInitiation of therapyCourse of therapyVA hospital systemIleocolonic diseaseVA cohortCohort studyVeteran patientsMedical recordsRisk factorsCommon reasonPatientsDiscontinuationTherapy